UNSPSC 85753209: Revision of autologous tissue substitute in testis, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to revision of autologous tissue substitute in testis, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 0VWD37Z

UNSPSC 85753209 Revision of autologous tissue substitute in testis, percutaneous approach is a Commodity code that shows little relevant recent activity in state and local procurement. The code nominally describes a specific urological surgical procedure, but the recent opportunities posted under this code do not align with the code's clinical scope. Instead, state and local issuers have tagged opportunities spanning occupational medical surveillance, independent disability medical evaluation services, surgical benefit program management through Centers of Excellence networks, pharmacy benefit administration, temporary health professional staffing, and emergency medical services for detained youth. These opportunities represent administrative healthcare contracting, benefits program management, and staffing services — none involve autologous tissue procedures or direct surgical intervention. The mismatch suggests either miscoding by procurement offices or a data classification artifact rather than genuine demand for the service the code nominates.

The issuing bodies posting under this code include city retirement offices (City of Phoenix), municipal health systems (City of Long Beach, County of Santa Clara Health System), state transportation agencies (Washington State Department of Transportation), county probation departments (Harris County Juvenile Probation Department), and county government service divisions (Collier County Board of County Commissioners). Recent opportunities span Arizona, California, Washington, Texas, and Florida, with response dates ranging from September through October 2026. Unless procurement offices begin tagging urological tissue procedures or regenerative medicine services under this code, the Commodity code itself does not appear to be a meaningful avenue for suppliers of the service it nominally describes.